Evidence map›Paper›PMID 30881854›Full record

ArticleIntractable & rare diseases research2019

Propranolol and ascorbic acid in control of fibrodysplasia ossificans progressiva flare-ups due to accidental falls.

Durval Batista Palhares, Deborah Ribeiro Nascimento, Marilene Garcia Palhares, Suzana Lopes, Liane de, Paula Cristhina, José Mauro, Fabiana Alves, Rancisco Oliveira Vieira, Elaine Maria Souza-Fagundes and 4 more

Open access · diamondAbstract read
In one paragraph

Article in Intractable & rare diseases research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Durval Batista PalharesUFMS/ Faculty of Medicine, Campo Grande, MS, Brazil.
Deborah Ribeiro NascimentoUFMS/ Faculty of Medicine, Campo Grande, MS, Brazil.
Marilene Garcia PalharesUFMS/ Faculty of Medicine, Campo Grande, MS, Brazil.
Suzana LopesUFMS/ Faculty of Medicine, Campo Grande, MS, Brazil.
Liane deUFMS/ Faculty of Medicine, Campo Grande, MS, Brazil.
Paula CristhinaUFMS/ Faculty of Medicine, Campo Grande, MS, Brazil.
José MauroProcter & Gamble Health Care & Global Clinical Sciences, Mason, OH, USA.
Fabiana AlvesUFMG/ Department of Physiology and Biophysics, Belo Horizonte, MG, Brazil.
Rancisco Oliveira VieiraUFMG/ Department of Physiology and Biophysics, Belo Horizonte, MG, Brazil.
Elaine Maria Souza-FagundesUFMG/ Department of Physiology and Biophysics, Belo Horizonte, MG, Brazil.
Adam UnderwoodThe Walsh University, Division of Mathematics and Sciences, North Canton, OH, USA.
Amy MilstedThe Walsh University, Division of Mathematics and Sciences, North Canton, OH, USA.
Robson AugustoUFMG/ Department of Physiology and Biophysics, Belo Horizonte, MG, Brazil.
Almir Sousa MartinsUFMG/ Department of Physiology and Biophysics, Belo Horizonte, MG, Brazil.
Instituto Metodista Izabela Hendrix · BRWalsh University · USProcter & Gamble (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fibrodysplasia ossificans progressiva (FOP) is a rare, intractable and devastating genetic connective tissue disorder characterized by progressive ectopic ossification in the soft tissues and skeleton. Three patients, one teenage girl (P1), one male adult (P2) and one male child (P3), were studied and treated with FOPCON (combined formulation of 14 mg of propranolol and 250 mg of ascorbic acid), given three times per day. P1 started treatment in March 2012, P2 in October 2012 and P3 in July 2015. The clinical follow-up of these three patients, before initiating treatment with FOPCON, showed that FOP flare-ups used to occur frequently and that under FOPCON therapy, none of these patients had flare-ups. The striking feature of this treatment with FOPCON, is that, all three cases suffered accidental falls with documented injures until complete healing and that where major flare-ups should occur, injures or sequels, there was none. The present clinical observation shows that ascorbic acid plus the nonspecific beta blocker propranolol can be effectively useful, when administered previously and continually, in the prophylaxis of FOP flare-ups, especially for accidental falls. In this regard, FOPCON could be a prophylactic aid in cases of surgery of patients with FOP, hoping that it may benefit patients from having the severe sequels, characteristic of heterotopic bone formation. All three patients reported, to date, they no longer had flare-ups nor heterotopic ossification and showed normal scar healing.

Indexed as

beta blockerectopic ossificationFOPCONVitamin C

Identifiers

PMID30881854
PMCPMC6409115
OpenAlexW2915450290

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.